Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26646496 | 0.97 | ADRB1 (0.35) | ADRB1ALDH1A1LMNAHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL12818396 | 0.97 | ALDH1A1 (0.37) | ADRB1ALDH1A1LMNAHTR3EHTR3B | |
| Hydrazine SCHEMBL27569857 | 0.94 | ADRB1 (0.34) | ADRB1ALDH1A1LMNAHTR3EHTR3B | |
| Benzene SCHEMBL27534755 | 0.92 | SIGMAR1 (0.39) | ADRB1ALDH1A1HTR3EHTR3BHTR1D | |
| Propane SCHEMBL28275423 | 0.89 | ADRB1 (0.32) | ADRB1 | |
| SCHEMBL19343650 | 0.89 | CXCR4 (0.35) | ADRB1ALDH1A1 | |
| SCHEMBL26645919 | 0.87 | ADRB1 (0.31) | ADRB1 | |
| SCHEMBL13555457 | 0.82 | — | — | |
| Pyridine SCHEMBL28115254 | 0.80 | PLD1 (0.38) | ADRB1ALDH1A1HTR3EHTR3BHTR1D | |
| SCHEMBL29649161 | 0.77 | ADRB1 (0.34) | ADRB1ALDH1A1LMNAHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502386-B2 | Nitrogen-containing heterocyclic compound and use thereof | Shanghai Shijiang Biotechnology Co., Ltd. (CN) | 2025-12-23 | — | — | US | claimed |
| US-20250197415-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) | 2025-06-19 | — | — | US | claimed |
| US-20250197389-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) | 2025-06-19 | — | — | US | claimed |
| CN-110156772-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-104926801-B | Substituted azetidine analog derivative, the pharmaceutical composition containing it and its application in antitumor | 浙江大学 | 2019-06-04 | — | — | CN | claimed |
| CN-109496211-A | A kind of piperazine derivative of anti-candida albicans and the preparation method and application thereof | 华南农业大学 | 2019-03-19 | — | — | CN | claimed |
| CN-109384680-A | A kind of preparation method of flibanserin intermediate | 广州朗圣药业有限公司 | 2019-02-26 | — | — | CN | claimed |
| CN-108017659-A | Benzimidazole and thiazole carboxamides class compound and its application | 沈阳药科大学 | 2018-05-11 | — | — | CN | claimed |
| CN-107200711-A | A kind of new technology for preparing flibanserin | 葵花药业集团北京药物研究院有限公司 | 2017-09-26 | — | — | CN | claimed |
| CN-106966991-A | A kind of new technology for preparing flibanserin | 葵花药业集团北京药物研究院有限公司 | 2017-07-21 | — | — | CN | claimed |
| CN-106699670-A | Benzimidazolyl piperazine compounds, preparation method thereof and pharmaceutical composition | 辽宁艾美生物医药产业有限公司 | 2017-05-24 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| CN-103797022-B | The method of purification of betulonic acid and Boc-Methionin betulonic acid, and utilize bridged piperazine derivatives to prepare the methodology of organic synthesis of betulonic acid acid amides | KOREA INSTITUTE OF ENERGY RESEARCH (KR) | 2016-04-20 | — | — | CN | claimed |
| CN-103797022-A | Method of purifying betulonic acid and boc-lysinated betulonic acid, organic synthesis method of preparing piperazine betulonic acid amide by using a piperazine derivative | KOREA ENERGY RESEARCH INST | 2014-05-14 | — | — | CN | claimed |
| CN-102060712-A | Method for preparing 4-trifluoromethylphenyl piperazine | JUNKAI TIANJIN CHEMICAL CO LTD | 2011-05-18 | — | — | CN | claimed |
| EP-2300469-A2 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | claimed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | claimed |
| US-12502386-B2 | Nitrogen-containing heterocyclic compound and use thereof | Shanghai Shijiang Biotechnology Co., Ltd. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-0034249-A2 | New naphthimidazole and naphthoxazole derivatives, their preparation, and their use in pharmaceuticals | GRUPPO LEPETIT S.P.A. (IT) | 1981-08-26 | — | — | EP | disclosed |
| US-4107437-A | SEDATIVES, ANTIARRHYTHMIA AGENTS | PARCOR (FR) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197389-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | PPIF, PIN1, NME4 | ADRB1 4671/4885ALDH1A1 3141/4885LMNA 2301/4885 |
| US-20250197415-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | UHRF1, NNMT, EHMT1 | ADRB1 3508/4885ALDH1A1 956/4885LMNA 4217/4885 |
| US-12502386-B2 | Nitrogen-containing heterocyclic compound and use thereof | UHRF1, NNMT, EHMT1 | ADRB1 3508/4885ALDH1A1 956/4885LMNA 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.